
Tirzepatide and semaglutide are the two most effective weight-loss medications available today, and both are once-weekly injections. Semaglutide activates one hormone receptor, GLP-1. Tirzepatide activates GLP-1 plus a second receptor, GIP.
The short answer: in the first head-to-head obesity trial, tirzepatide produced about 20% average weight loss at 72 weeks, compared with about 14% for semaglutide. Semaglutide has the longer track record and proven heart-attack and stroke reduction. Both are FDA-approved and available by prescription.
Both drugs mimic gut hormones that your body releases after you eat:
Semaglutide acts on GLP-1 only. Tirzepatide acts on both GLP-1 and GIP. That second receptor is the main reason tirzepatide produces more weight loss at its top dose.
Tirzepatide wins the only direct comparison. SURMOUNT-5 randomized 751 adults with obesity (and without diabetes) to the highest tolerated dose of tirzepatide or semaglutide for 72 weeks. Published in the New England Journal of Medicine, it found average weight loss of 20.2% with tirzepatide versus 13.7% with semaglutide.
Semaglutide is still a highly effective drug. In its own pivotal trial, STEP 1, people on semaglutide 2.4 mg lost an average of 14.9% of their body weight at 68 weeks, versus 2.4% on placebo. For many people, that's enough to reach their goal.
Both lower blood sugar substantially. In SURPASS-2, a 40-week trial of 1,879 people with type 2 diabetes, tirzepatide lowered A1C by 2.0 to 2.3 points, compared with 1.86 points for semaglutide 1 mg. Tirzepatide also produced more weight loss at every dose. One caveat: semaglutide's 1 mg dose was the highest diabetes dose available when the trial began, and higher doses now exist.
Semaglutide has the stronger evidence today. In SELECT, a trial of 17,604 adults with overweight or obesity and existing heart disease (but no diabetes), semaglutide reduced heart attacks, strokes, and cardiovascular deaths by 20% compared with placebo. Wegovy is approved for this use.
Tirzepatide lowers blood pressure, triglycerides, and waist size, all of which point toward heart benefit, and large cardiovascular outcome trials are underway. If you have established heart disease, this is worth discussing with your clinician.
Both share the same main side effects, which are digestive and most common while the dose is being increased:
Despite causing more weight loss, tirzepatide was slightly easier to tolerate in the head-to-head trial: 2.7% of people stopped tirzepatide because of digestive side effects, compared with 5.6% on semaglutide. Starting low, increasing slowly, eating smaller meals, and staying hydrated help with both.
Both carry the same warnings, including a boxed warning about thyroid C-cell tumors seen in rodents, and caution around pancreatitis and gallbladder disease. Neither should be used during pregnancy.
Semaglutide, yes. Rybelsus is a daily semaglutide pill for type 2 diabetes, and in December 2025 the FDA approved the Wegovy pill, a daily oral semaglutide for weight loss. The pill must be taken on an empty stomach with a small sip of water, 30 minutes before eating.
Tirzepatide is available only as an injection.
Yes. Switching is common, especially for people whose weight loss has stalled on semaglutide or who had trouble with side effects. Your clinician will usually start tirzepatide at a dose that matches where you are in treatment, then adjust. You should never take the two together.
Tirzepatide may be better if you:
Semaglutide may be better if you:
For most people focused on weight loss, tirzepatide is the more effective choice. Semaglutide remains an excellent option, and the best medication is the one you can stay on consistently.
For weight loss, yes. In a direct 72-week trial, tirzepatide produced 20.2% average weight loss compared with 13.7% for semaglutide.
Yes. Tirzepatide is the active ingredient in Zepbound (for weight loss and sleep apnea) and Mounjaro (for type 2 diabetes).
Both contain semaglutide. Wegovy is approved for weight loss and heart-risk reduction at doses up to 2.4 mg. Ozempic is approved for type 2 diabetes at doses up to 2 mg.
Both reduce appetite within the first week or two. Weight loss is usually similar early on because both start at low doses. The difference grows over months as doses increase.
Most people regain some weight after stopping either medication. Treating them as long-term therapies, or tapering with a plan for nutrition and exercise, gives the best chance of keeping weight off.
Yes. Both are peptides, short chains of amino acids engineered to mimic natural gut hormones.
Tirzepatide produces more weight loss; semaglutide has the longer track record and proven heart protection. In the only direct comparison, tirzepatide led to about 20% average weight loss versus about 14% for semaglutide, with fewer people stopping because of side effects.
Bowery Clinic offers both Tirzepatide and Semaglutide after a quick online evaluation. Compare more options in our guides to retatrutide vs tirzepatide, peptides vs GLP-1s, and peptides for weight loss. See what our patients say.

